Skip to main
SLDB

Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences (SLDB) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 55%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Solid Biosciences Inc is positioned favorably due to the successful outcomes observed in its cardiac measures, where stable-to-improved left ventricular ejection fraction (LVEF) was reported, particularly among a subset of patients with previously low LVEF. The company has enhanced its program's probability of success to 60% following consistent positive data, indicating a potential for attractive market positioning in the future. Furthermore, with a projected year-end cash balance of $188 million and ongoing advancements in the Phase 3 IMPACT DUCHENNE trial, Solid Biosciences appears well-equipped to sustain its research initiatives and navigate regulatory pathways effectively.

Bears say

Solid Biosciences Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily due to potential safety issues and regulatory hurdles for its lead product, SGT-003, aimed at treating Duchenne muscular dystrophy. The company's projections for market penetration and sales may experience dramatic downward revisions if the drug fails to secure regulatory approval or faces manufacturing constraints, impacting its ability to capitalize on expected growth opportunities. Additionally, the inherent risks associated with clinical development and competition in the biotechnology sector further exacerbate concerns related to the company's financial stability and growth potential.

Solid Biosciences (SLDB) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 55% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solid Biosciences (SLDB) Forecast

Analysts have given Solid Biosciences (SLDB) a Buy based on their latest research and market trends.

According to 11 analysts, Solid Biosciences (SLDB) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solid Biosciences (SLDB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.